Emil T. Lin
PERFORMING ORGANIZATION NAME(S) AND ADORESS(ES) S.PERFORMING ORGANIZATIONSchool of Pharmacy
REPORT NUMBERUniversity of California San Francisco, CA 94143
SPONSORINGi MONITORING AGENCY NAME(S) AND ADORESS(ES)il0
ABSTRACT (Mdaxmum 200wOrWjWork on development and/or validation of analytical methodologies during the first half of the contrac focused on assays for WR 238,605, halofantrine (and its metabolite), WR 6026 (and its metabolites), mefloquine (and its metabolite), artelinic acid, p-aminoheptanophenone (and related compounds), and primaquine (and its metabolite). Work on routine analyses of biological specimens during this period was performed for studies that required determination of concentrations of WR 238,605, halofantrine (and its metabolite), WR 6026 (and its metabolites), mefioquine (and its me: m~lite), paminoheptanophenone (and related compounds), and primaquine (and its metabolite). Where copyrighted material is quoted, permission has been obtained to use such material.Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.In conducting research using animals, the investigator(s) adhered to the *Guide for the Care and Use of Laboratory Animals,O prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CPR 46.In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories. For many years our research group has been actively involved in the development of analytical methods to assay for drug substances in biological fluids for pharmacokinetic, bioavailability, drug metabolism and drug monitoring studies. This report describes the approach we took to develop sensitive (nanograms per milliliter of biological matrix), specific and quantitative analytical methods to support pharmacokinetic and bioavailability studies of candidate chemical warfare antidotes, antiparasitic drugs, radioprotectants and anti-infectious disease drugs.In addition, routine analyses of biological specimens to support pharmacokinetic and bioavailability studies as part of preclinical and clinical investigations undertaken for the purpose of new drug development were performed as a significant adjunct to method development obje...